Otulana acquired 25,000 shares at a price of 38.8 US cents each, and now holds 50,000 shares.
Allergy Therapeutics closed up 0.7% to
Fri, 16th Mar 2018 17:30
Otulana acquired 25,000 shares at a price of 38.8 US cents each, and now holds 50,000 shares.
Allergy Therapeutics closed up 0.7% to
IN BRIEF: Allergy Therapeutics study confirms peanut vaccine potential
Read more(Sharecast News) - Pharmaceutical biotechnology company Allergy Therapeutics announced positive primary results from an ex-vivo biomarker study on Tuesday, evaluating its novel virus-like particle (VLP)-based peanut allergy vaccine candidate, VLP Peanut.
Read moreAllergy Therapeutics expects revenue rise in year despite challenges
Read moreTRADING UPDATES: Vitec and Allergy Therapeutics lift full-year outlook
Read more(Sharecast News) - Commercial biotechnology company Allergy Therapeutics said on Thursday that full-year operating profits were expected to be "well ahead" of market expectations thanks to "significantly lower" expenses.
Read moreTRADING UPDATES: Superdry optimistic; Virgin Wines toasts demand surge
Read more(Sharecast News) - Commercial biotechnology company Allergy Therapeutics announced the completion of the treatment of all patients in its 'G309' exploratory field study to evaluate the efficacy and safety of Grass MATA MPL in subjects with seasonal allergic rhinitis or rhinoconjunctivitis, induced by grass pollen.
Read moreTRADING UPDATES: Capita sells Irish unit; Daily Mail buys science mag
Read more(Sharecast News) - Commercial biotechnology company Allergy Therapeutics reported a 7% improvement in its revenue in actual terms in its interim results on Wednesday, and 5% growth at constant rate, to £54.0m.
Read moreIN BRIEF: Allergy Therapeutics Hails Growth; Non-Exec Smith To Leave
Read moreIN BRIEF: Allergy Therapeutics And Imperial Start Peanut Allergy Study
Read more(Sharecast News) - Speciality allergy-focussed pharmaceutical company Allergy Therapeutics announced on Tuesday that an ex-vivo biomarker study of blood samples from peanut allergy patients had started at Imperial College London.
Read moreIN BRIEF: Allergy Therapeutics Shareholders Revolt At General Meeting
Read moreUK Shareholder Meetings Calendar - Next 7 Days
Read moreUK DIRECTOR DEALINGS SUMMARY: Landsec CEO Buys GBP300,000 Worth
Read more